Strategic Alliances, Joint Ventures and Licensing Transactions TRANSACTIONAL

WilmerHale's Strategic Alliances, Joint Ventures and Licensing Transactions lawyers leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovate and effective technology-related agreements.


In the highly competitive worlds of biotechnology and information technology, licensing transactions and strategic alliances can make the difference between success and failure. The attorneys in WilmerHale's Technology Transactions and Licensing Practice—many of whom have backgrounds in computer engineering, biochemistry, and other technical fields—collaborate closely with our corporate, licensing, intellectual property and tax lawyers to negotiate agreements for clients across a broad spectrum of industries. They handle hundreds of complex joint ventures, strategic alliances, and outsourcing and licensing transactions each year, some of which span international borders. Their work often receives industry commendation for its significance in shaping the future of science and technology.

Contacts

Sort By
Barrett, Steven D.

Steven D. Barrett

Co-Chair, Technology Transactions and Licensing Practice Group

+1 617 526 6238 (t)

steven.barrett@wilmerhale.com

Juran, Belinda M.

Belinda M. Juran

Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6987 (t)

belinda.juran@wilmerhale.com

Bain, Mick

Mick Bain

Partner

+1 617 526 6158 (t)

michael.bain@wilmerhale.com

Boot, Jeannette K.

Jeannette K. Boot

Partner

+1 212 295 6507 (t)

jeannette.boot@wilmerhale.com

Borden, Mark G.

Mark G. Borden

Partner

+1 617 526 6675 (t)

mark.borden@wilmerhale.com

Bothwick, Jay E.

Jay E. Bothwick

Partner

+1 617 526 6526 (t)

jay.bothwick@wilmerhale.com

Braun, Martin

Dr. Martin Braun

Partner

+49 69 27 10 78 207 (t)

martin.braun@wilmerhale.com

Brown, Lillian

Lillian Brown

Partner

+1 202 663 6743 (t)

lillian.brown@wilmerhale.com

Buckland, Peter

Peter Buckland

Partner

+1 650 858 6036 (t)

peter.buckland@wilmerhale.com

Conahan, Joseph B.

Joseph B. Conahan

Partner

+1 617 526 6317 (t)

joseph.conahan@wilmerhale.com

Experience

We represent market leaders in life sciences, technology, energy and cleantech, communications, financial services and other industries. These companies include: 

  • Cutting-edge biotech developers Agios, Epizyme, Macrogenics, Merrimack, Ophthotech and Vedanta;
  • Gene-therapy innovators Spark Therapeutics and Editas;
  • Pharmaceutical companies Bristol-Myers Squibb and Vertex;
  • Personalized medicine company Kew Group;
  • Consumer electronics companies Bose and TiVo;
  • Data analysis pioneers Cellebrite, Kensho and Thasos;
  • FinTech innovators MineralTree and Qapital, as well as financial services providers American Express and MFS Investment Management;
  • Hardware developers and manufacturers Analog Devices and SanDisk;
  • Software and IT developers Toyota InfoTechnology Center and Progress Software;
  • Telecommunications leaders Altiostar, Broadcom and Cincinnati Bell;
  • Healthcare IT innovator Caradigm;
  • Video game developer Harmonix;
  • Artificial intelligence developer MetaMind Entertainment; and
  • Filmmaking and technology company Wymsee. 

Read more about the transactions we've done.

Life Sciences

Helping clients protect their innovations, forge strategic alliances and successfully navigate a complex, dynamic industry.

For companies in the life sciences sphere, licensing intellectual property and establishing strategic alliances are critical. WilmerHale's experienced licensing lawyers shepherd biotech, pharmaceutical, healthcare and medical device clients of all sizes through the complex transactions that make their business possible. Our attorneys excel at brokering material transfer agreements, manufacturing and supply agreements, confidentiality agreements and distribution agreements. They also frequently represent biotech venture capital clients as they license patents—the foundations of their companies—from leading academic institutions across the United States and Europe. Backed not only by their own experience but also the deep well of knowledge possessed by the firm's patent, tax, antitrust and EU competition lawyers, our transactional attorneys are ready to handle even the most multifaceted matters.

Hardware, Software, IT and Services

We assist with hundreds of agreements each year, guiding clients in nearly every technological field through the transactions that allow them to lead and innovate.

Our clients in the ever-changing and fiercely competitive hardware, software, IT and services depend on us to strategize and negotiate transactions that take advantage of opportunities now while protecting their innovations and shoring up strong industry relationships for the future. We structure, negotiate and draft all types of licensing, distribution, product development, joint venture and strategic alliance agreements for these clients, often drawing on the deep experience of WilmerHale's regulatory, intellectual property, business and tax lawyers. Our attorneys keep a close watch on Internet-related legislative and regulatory developments in the United States, the European Union and elsewhere, and leverage our up-to-the-minute knowledge to advise clients in areas such as data privacy and security, copyright infringement, and export restrictions.

Outsourcing

A top-tier practice that represents clients in sophisticated information technology, business process and other outsourcing transactions around the globe.

Our attorneys have extensive outsourcing experience; we have represented clients in more than 200 major outsourcing transactions. We assist our clients in all aspects of these transactions, including preparing and negotiating the services agreement and related exhibits, and continuing to advise our clients throughout the negotiations and life cycle of the relationships. The firm has leading complementary practices related to outsourcing transactions in areas such as data security and privacy, intellectual property, employment, tax, governance and dispute resolution, among others. In addition, we advise clients in the regulatory-related issues that arise through our top-tier financial services and other regulatory practices. Clients also benefit from our many years of practical experience in structuring agreements that enhance long-term performance and help achieve strategic objectives. We are quite familiar with emerging outsourcing models and new technologies that are influencing the marketplace, such as cloud computing and autonomic.

Recognition

  • Best Lawyers in America – Recognized nearly 100 WilmerHale partners in 2015, naming nine "Lawyer of the Year," including David Westenberg as Boston Information Technology Law Lawyer of the Year. From 2010-2013, WilmerHale's Technology Law practice received a number one ranking.
  • BioPharm Insight – Consistently lists our attorneys among the leading legal advisors for biotech and pharma licensing agreements in the global, North American and European and Asia-Pacific ranking tables. 
  • Chambers Global – Named WilmerHale among the best in the United States in outsourcing in 2014 and 2015.
  • Chambers USA: America's Leading Lawyers for Business – Named the firm in 2016 among the best in Massachusetts in technology, and in 2014 and 2015 among the best in the nation in technology and outsourcing. The "enormously respected" Robert Finkel is recognized for his significant technology experience and "practical approach and negotiation style." He is also named a "thought leader in the sourcing industry" with "unparalleled" industry knowledge.
  • LMG Life Sciences – Ranked the firm in its 2013-2016 editions in the areas of patent prosecution, patent strategy and management, general patent litigation, Hatch-Waxman patent litigation, corporate, licensing and collaboration, M&A, venture capital and white collar/government investigations. The firm was also named a "Lifecycle Firm," meaning the firm is regarded as one of the best full-service law firms serving the life sciences industry. Co-Chairs Steven Barrett and Belinda Juran have also been named "Life Sciences Stars." 
  • Super Lawyers – Named Co-Chair Steven Barrett a "Massachusetts Super Lawyer" in the 2014 edition of Boston Magazine.
  • The Legal 500 United States – Recognized Co-Chair Belinda Juran in 2013 as "a fantastic collaborator" and "outstanding in licensing."
  • U.S. News - Best Lawyers® – In the 2017 "Best Law Firms" rankings, our technology law practice was ranked in the second-tier nationally and in the first-tier in Boston. Our information technology law practice was ranked in the third-tier nationally and second-tier in Boston.
  • Who's Who Legal – Recognized Co-Chair Steven Barrett as a leader in life sciences in the 2015 edition.

Publications & News

View

November 8, 2016

WilmerHale Reps Infinity Pharma in $28M Licensing Agreement with Verastem

The WilmerHale deal team was led by Partners Belinda Juran and Steven Singer and included Associate Alex Civetta.

May 27, 2016

WilmerHale Lawyers and Practices Recognized in 2016 Edition of Chambers USA

Chambers USA: America's Leading Lawyers for Business announced its final rankings for the 2016 edition, with WilmerHale ranking among the nation's best in 47 practice area categories. Chambers also ranked 82 WilmerHale lawyers as leaders in their respective fields.

May 3, 2016

Selected 2016 Life Sciences Transactions

Recognized both globally and nationally for its leading life sciences practice, WilmerHale has more than four decades of experience representing biotechnology, pharmaceutical and medical device companies at all stages of growth, as well as venture capitalists and investment banks.

May 3, 2016

Selected 2016 Strategic Alliances, Joint Venture and Licensing Transactions

Our corporate, licensing, intellectual property and regulatory lawyers regularly handle a broad range of strategic alliance, joint venture, licensing,
collaboration, product development, outsourcing, manufacturing, distribution and similar agreements, including many significant deals that are helping to shape the future of science, technology and commerce.

May 2, 2016

WilmerHale Expands West Coast Corporate Practice With Two Partner Hires

WilmerHale is pleased to welcome Partners Christopher Rose and Eric Hwang to the firm's Los Angeles and Palo Alto offices, respectively.

March 24, 2016

2016 Corporate Reports

WilmerHale's annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.

December 21, 2015

The Medicines Company Agrees to Divest its Hemostasis Portfolio to Mallinckrodt plc

On December 18, The Medicines Company (NASDAQ:MDCO) announced that it entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt plc will acquire The Medicines Company’s global portfolio of three hemostasis products – RECOTHROM® Thrombin topical (Recombinant), PreveLeak™, and RAPLIXA™ (fibrin sealant) – for a total potential consideration of up to $410 million.

December 11, 2015

Neon Therapeutics Enters License Agreement with Broad Institute, Dana-Farber and Mass General

On December 9, 2015, Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, announced that the company has entered into a license agreement with the Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital.

September 14, 2015

LMG Life Sciences Release 2015 Rankings, Again Names WilmerHale a "Life Cycle Firm"

In its latest edition, LMG Life Sciences recognizes eight WilmerHale practice areas and 16 attorneys, and for the fourth consecutive year names WilmerHale a "Life Cycle Firm."

May 6, 2015

Selected 2015 Life Sciences Transactions

Recognized both globally and nationally as a leading life sciences practice, WilmerHale has four decades of experience representing biotechnology, pharmaceutical and medical device companies at all stages of growth, as well as venture capitalists and investment banks.